Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase I trial of vinflunine and pemetrexed in refractory solid tumors.

Investigational new drugs - 1 Feb 2011

Sanoff Hanna K, Davies Janine, Walko Christine, Buie Larry, Chiu Wing-Keung, Ivanova Anastasia, O'Neil Bert, Stinchcombe Thomas E, Keller Kimberly, Dees E Claire

Abstract excerpt

BACKGROUND: Vinflunine is a novel vinca alkaloid with promising single agent clinical activity. Pemetrexed has at least additive activity with other vincas. A phase I trial was undertaken to assess the safety of vinflunine and pemetrexed in patients with refractory solid tumors. METHODS: A standard 3-patient cohort dose escalation scheme was used to determine the dose-limiting toxicity (DLT) and maximum tolerated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Cytochrome P-450 CYP3A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glutamates

Share to Guanine

Share to Midazolam

Share to Pemetrexed

Share to Statistics, Nonparametric

Share to Vinblastine

Source

Open in PubMed Open full text

Identifiers

PMID: 19830387
DOI: 10.1007/s10637-009-9344-3
PMCID: PMC3143820

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Phase I trial of vinflunine and pemetrexed in refractory solid tumors.PMID 19830387Read ↗

A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors.Semantic proximity Read ↗

Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenograftsSemantic proximity Read ↗

Phase Ia/Ib trial of the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M).Semantic proximity Read ↗

Vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro.Semantic proximity Read ↗

Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutations.Semantic proximity Read ↗

Next Generation Antineoplastic Agents: A Review on Structurally Modified Vinblastine (VBL) AnaloguesSemantic proximity Read ↗

Metronomic oral vinorelbine doublet chemotherapy with carboplatin in treatment of advanced lung cancer: a feasibility and safety studySemantic proximity Read ↗

Newer Cytotoxic Agents: Attacking Cancer BroadlySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.